γμβ μϊελο δςξεγ

ρψβμ πβιωεϊ

 

|
ξϊλεπιν (6,402)
|
αλμ δΰϊψ

ψαμιξιγ 15 ξ"β

ων δϊψετδ αΰπβμιϊ: Revlimid ® 15 Mg. ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
αρμ δαψιΰεϊ αρμ δαψιΰεϊ
|
ωϊσ α-

φεψϊ ξϊο

PER OS

ξιπεο

Capsules

ωιξεω αϊψετδ

REVLIMID is indicated for 1. Treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.3. Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

ξρτψ ψιωεν

140 47 31662 14

ιφψο

Celgene Europe Ltd, Uk

ϊεχσ ψιωιεο μϊψετδ

04/2014 - 04/2024

δϊλπιν δξετιςιν αΰϊψ ζδ πεςγε μρτχ ΰιπτεψξφιδ λμμιϊ αμαγ.
ΰιπν ξδεειν δξμφδ, ϊημισ μδϊιιςφεϊ ςν ξεξηδ ΰε χαμϊ ιιςευ ψτεΰι.
αωιξεω ΰε φτιιδ απϊεπιν ωαΰϊψ διπκ ξΰωψ ΰϊ ϊπΰι δωιξεω αΰϊψ.
ηεξψ τςιμ ψιλεζ / λξεϊ αιηιγϊ ξιπεο
Lenalidomide 15 MG
ΰψιζδ λξεϊ αΰψιζδ ηιι ξγσ ϊψετϊ ξψων
Blister pvc/pctfe 21 x CAPSULES ηεγωιν 36 μΰ

*

*

χιωεψιν ιδτλε αΰετο ΰεθεξθι μμηιφιν
 

αωμιηϊ ϊβεαδ ΰπι ξχαμ ΰϊ ϊπΰι δωιξεω αΰϊψ.

 
δψων μΰϊψ εχαμ ςγλεπιν ιωιψεϊ μγεΰ"μ ωμκ!
 

ξηωαεο δψιεο

λμ δτψθιν ςμ δδψιεο ωμκ. λπρι: μξηωαεο δψιεο »
60 χμεψιεϊ
ξψχ ΰτεπδ
ξψχ ΰτεπδ ιαωδ θςιν, αψιΰ εχμ μδλπδ - ΰηγ δξψχιν δΰδεαιν αιεϊψ αηεψσ